Back to Trades
Total Value
$3.9M
Net $3.9M sold
Filing Date
Jul 9, 2026
1 transaction
Sales
$3.9M
1 transaction
Trade Summary
On Jul 7, 2026, ORBIMED ADVISORS LLC, Director, sold $3.9M of Sionna Therapeutics, Inc. (SION) across 1 transaction. The filing covers Common Stock and reflects net selling of $3.9M. Reported prices ranged from $44.86. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Sionna Therapeutics, Inc.
- Ticker Symbol
- SION
- CIK
- 0002036042
Insider Information
- Role
- Director
- Location
- NEW YORK, NY
Filing Details
- Filing Date
- Jul 9, 2026
- Transaction Date
- Jul 7, 2026
- Accession Number
- 0000947871-26-000694
- Form Type
- 4
- Net Trading Amount
- -$3.9M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 7, 2026 | Common Stock | 85,918 | $44.86 | Sale | $3.9M |
Want live alerts when ORBIMED ADVISORS LLC trades again?
Download Insider Trades to track SION, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)These securities were sold pursuant to a 10b5-1 plan.
- (F2)These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
- (F3)This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.